These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
302 related articles for article (PubMed ID: 19578355)
41. [How to use PSA in 2009]. Ponholzer A; Stoiber F; Loidl W; Rauchenwald M; Schramek P; Madersbacher S Wien Med Wochenschr; 2009; 159(21-22):515-20. PubMed ID: 19997836 [TBL] [Abstract][Full Text] [Related]
42. Determination of the percentage of free prostate-specific antigen helps to avoid unnecessary biopsies in men with normal rectal examinations and total prostate-specific antigen of 4-10 ng/ml. Martínez-Piñeiro L; Tabernero A; Contreras T; Madero R; Lozano D; López-Tello J; Alonso-Dorrego JM; Picazo ML; González Gancedo P; Martínez-Piñeiro JA; de La Peña JJ Eur Urol; 2000 Mar; 37(3):289-96. PubMed ID: 10720854 [TBL] [Abstract][Full Text] [Related]
44. Simultaneous quantification of prostate-specific antigen and human glandular kallikrein 2 mRNA in blood samples from patients with prostate cancer and benign disease. Ylikoski A; Pettersson K; Nurmi J; Irjala K; Karp M; Lilja H; Lövgren T; Nurmi M Clin Chem; 2002 Aug; 48(8):1265-71. PubMed ID: 12142383 [TBL] [Abstract][Full Text] [Related]
45. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. Darson MF; Pacelli A; Roche P; Rittenhouse HG; Wolfert RL; Young CY; Klee GG; Tindall DJ; Bostwick DG Urology; 1997 Jun; 49(6):857-62. PubMed ID: 9187691 [TBL] [Abstract][Full Text] [Related]
46. Serum markers in prostate cancer detection. Bratt O; Lilja H Curr Opin Urol; 2015 Jan; 25(1):59-64. PubMed ID: 25393274 [TBL] [Abstract][Full Text] [Related]
47. Prespecified 4-Kallikrein Marker Model at Age 50 or 60 for Early Detection of Lethal Prostate Cancer in a Large Population Based Cohort of Asymptomatic Men Followed for 20 Years. Vertosick EA; Häggström C; Sjoberg DD; Hallmans G; Johansson R; Vickers AJ; Stattin P; Lilja H J Urol; 2020 Aug; 204(2):281-288. PubMed ID: 32125228 [TBL] [Abstract][Full Text] [Related]
48. Re: The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men. Taneja SS J Urol; 2015 Jan; 193(1):127. PubMed ID: 25523657 [No Abstract] [Full Text] [Related]
49. Value of a Statistical Model Based on Four Kallikrein Markers in Blood, Commercially Available as 4Kscore, in All Reasonable Prostate Biopsy Subgroups. Vickers AJ; Vertosick EA; Sjoberg DD Eur Urol; 2018 Oct; 74(4):535-536. PubMed ID: 29903434 [No Abstract] [Full Text] [Related]
50. Prostatic specific antigen and bone scan in the diagnosis and follow-up of prostate cancer. Can diagnostic significance of PSA be increased? Bantis A; Grammaticos P Hell J Nucl Med; 2012; 15(3):241-6. PubMed ID: 23227460 [TBL] [Abstract][Full Text] [Related]
51. Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer. Becker C; Piironen T; Pettersson K; Hugosson J; Lilja H J Urol; 2003 Oct; 170(4 Pt 1):1169-74. PubMed ID: 14501718 [TBL] [Abstract][Full Text] [Related]
52. Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore. Verbeek JFM; Bangma CH; Kweldam CF; van der Kwast TH; Kümmerlin IP; van Leenders GJLH; Roobol MJ Urol Oncol; 2019 Feb; 37(2):138-144. PubMed ID: 30528698 [TBL] [Abstract][Full Text] [Related]
53. Prospective validation of microseminoprotein-β added to the 4Kscore in predicting high-grade prostate cancer in an international multicentre cohort. Lonergan PE; Vertosick EA; Assel M; Sjoberg DD; Haese A; Graefen M; Boorjian SA; Klee GG; Cooperberg MR; Pettersson K; Routila E; Vickers AJ; Lilja H BJU Int; 2021 Aug; 128(2):218-224. PubMed ID: 33306251 [TBL] [Abstract][Full Text] [Related]
54. Point: Impact of prostate-specific antigen velocity on management decisions and recommendations. Loeb S; Carter HB J Natl Compr Canc Netw; 2013 Mar; 11(3):281-5. PubMed ID: 23486454 [TBL] [Abstract][Full Text] [Related]
56. PSA and other tissue kallikreins for prostate cancer detection. Stephan C; Jung K; Lein M; Diamandis EP Eur J Cancer; 2007 Sep; 43(13):1918-26. PubMed ID: 17689069 [TBL] [Abstract][Full Text] [Related]
57. hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml. Raaijmakers R; de Vries SH; Blijenberg BG; Wildhagen MF; Postma R; Bangma CH; Darte C; Schröder FH Eur Urol; 2007 Nov; 52(5):1358-64. PubMed ID: 17499425 [TBL] [Abstract][Full Text] [Related]
58. Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml. Ornstein DK; Rayford W; Fusaro VA; Conrads TP; Ross SJ; Hitt BA; Wiggins WW; Veenstra TD; Liotta LA; Petricoin EF J Urol; 2004 Oct; 172(4 Pt 1):1302-5. PubMed ID: 15371828 [TBL] [Abstract][Full Text] [Related]
59. Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer. Steuber T; Vickers AJ; Serio AM; Vaisanen V; Haese A; Pettersson K; Eastham JA; Scardino PT; Huland H; Lilja H Clin Chem; 2007 Feb; 53(2):233-40. PubMed ID: 17185368 [TBL] [Abstract][Full Text] [Related]